rhesus rotavirus vaccine

01/01/1996 - "RRV-TV is highly protective against very severe, dehydrating rotavirus gastroenteritis."
07/01/2000 - "RRV-TV was also shown to be 75% protective against very severe gastroenteritis in northern Brazil. "
02/01/1998 - "RRV-TV has similar overall efficacy to RRV-S1, but provides greater protection against gastroenteritis caused by rotavirus strains of serotypes other than G1. "
08/01/2013 - "This study examined RRV-TV for the prevention of rotavirus gastroenteritis (RV-GE) in Ghana, West Africa, with infants receiving the first dose during the neonatal period and the second before 60 days of age. "
11/01/1999 - "Our reanalysis provides evidence that, at least against moderate/severe rotavirus gastroenteritis, RRV-TV, 4 x 10(4) pfu/dose is potentially as efficacious as RRV-TV, 4 x 10(5) pfu/dose, even in settings with very high rotavirus disease burden. "

10/23/1997 - "Although a rhesus rotavirus-based quadrivalent vaccine is highly effective in preventing severe diarrhea in developed countries, in developing countries its efficacy has been less impressive. "
11/01/1999 - "These trials should use catchment designs and focus on the evaluation of the efficacy of one or three doses of RRV-TV against moderate to severe/very severe rotavirus diarrhea."
10/01/1998 - "In clinical trials in industrialized countries, RRV-TV conferred 49% to 68% protection against any rotavirus diarrhea and 61% to 100% protection against severe disease. "
02/01/1996 - "Only the RRV vaccine induced a low level of protection against rotavirus diarrhea mainly of serotype G1 specificity. "
11/01/2000 - "Data from a large catchment trial in Venezuela with a higher RRV-TV dose, of 4 x 10(5) PFU/dose, indicated an efficacy rate of 48% against all rotavirus diarrhea and 88% against severe rotavirus diarrhea. "

09/02/2016 - "In this study, the effect of miR-29c and miR-129-5p on epithelial-mesenchymal transition (EMT) in experimental BA was explored by constructing BA mouse models via Rhesus rotavirus vaccine infection. "
10/01/2005 - "Our findings indicate that NSP4 evokes significantly (P < 0.05) higher seroconversion rates after natural infection than after RRV-TV vaccination. "
08/01/1991 - "In this article, we report the characterization of the intestinal antibody response of a murine model to heterologous infection with the rhesus rotavirus vaccine strain. "
05/31/2011 - "Also, RRV vaccine-induced antibodies were partially cross-protective against infection with a related alphavirus, Chikungunya virus, and did not enhance infection. "
10/01/2005 - "Following natural infection or RRV-TV vaccination, NSP4 was significantly less immunogenic than the VP6 protein when these responses were independently measured by ELISA. "

01/01/1993 - "Natural asymptomatic infections may enhance the efficacy of rhesus rotavirus vaccine. "

03/01/1990 - "The efficacy of a rhesus rotavirus vaccine (MMU 18006, serotype 3) against infantile diarrhea was evaluated by active home surveillance of a group of 320 children 1-10 months of age in Caracas, Venezuela. "